Antimicrobial peptide for nosocomial infections

Patent metadata

Field	Value
Publication number	US-2018222943-A1
Application number	US-201615747934-A
Country	US
Kind code	A1
Filing date	Jul 28, 2016
Priority date	Jul 30, 2015
Publication date	Aug 9, 2018
Grant date	—

Abstract

A novel antimicrobial peptide is provided having an inhibitory effect on biofilms produced by biofilm-forming bacteria. The peptide is effective against wide range bacterial targets; generates no antimicrobial resistance; agglutinates bacteria cells enhancing the pathogen removal at the infectious focus; promotes biofilm eradication and prevents biofilm development. Compositions comprising the peptide are provided to treat and prevent infectious diseases, and for other uses such as the disinfection of medical and surgical materials.

First claim

1 . A peptide consisting of the amino acid sequence:

X 1 -Pro 2 -X 3 -X 4 -X 5 -Ala 6 -Gln 7 -Trp 8 -Phe 9 -Ala 10 -Ile 11 -Gln 12 -

His 13 -Ile 14 -X 15 -Pro 16 -X 17 -X 18 -X 19 -Ala 20 -Met 21 -X 22 -Ala 23 -

Ile 24 -X 25 -X 26 -Tyr 27 -Arg 28 -Trp 29 -Arg 30 -X 31 -NH2

wherein:
X 1 , X 5 , X 17 , X 22 are amino acids selected from the group consisting of Arg and Lys,
X 3 is an amino acid selected from the group consisting of Phe, Leu, Ile and Val,
X 4 is an amino acid selected from the group consisting of Thr, Phe and Ile,
X 15 is any amino acid,
X 18 is an amino acid selected from the group consisting of Thr, Ser, Gln and Asn,
X 19 is an amino acid selected from the group consisting of Ile, Leu and Val,
X 25 is an amino acid selected from the group consisting of Asn, His, and Lys,
X 26 is an amino acid selected from the group consisting of Asn, Lys and Trp, and
X 31 is either absent or from one to nine amino acids selected from the group consisting of Asn, Gln, Ser and Thr.

2 . The peptide according to claim 1 , wherein the peptide has antimicrobial activity and has an inhibitory effect on biofilm formation by a biofilm-producing microorganism.

3 . A peptide consisting of an amino acid sequence which has a 90% identity to sequence SEQ ID NO: 1, wherein the peptide has antimicrobial activity and has an inhibitory effect on biofilm formation by a biofilm-producing microoganism.

4 . The peptide according to claim 3 , which consists of SEQ ID NO: 1.

5 . The use of a peptide as defined in claim 1 , as antimicrobial agent.

6 . The use of a peptide as defined in claim 1 , as antibiofilm agent.

7 . The use of a peptide as defined in claim 5 , for the disinfection of medical and surgical materials.

8 . The peptide as defined in claim 1 , for use as a medicament.

9 . The peptide according to claim 8 , for use in the treatment and/or prevention of infectious diseases.

10 . The peptide according to claim 9 , wherein the infectious disease is selected from the group consisting of a bacterial, a viral, a parasitic and a fungal disease.

11 . The peptide according to claim 10 , wherein the infectious disease is a bacterial disease and is caused by a Gram negative bacterial pathogen.

12 . The peptide according to claim 11 , wherein the Gram negative pathogen is selected from the group consisting of: Pseudomonas, Escherichia coli, Acinetobacter, Salmonella and Klebsiella.

13 . The pharmaceutical composition comprising the peptide as defined in claim 1 , and a pharmaceutical acceptable carrier, diluent or excipient.

14 . The composition comprising the peptide as defined in claim 1 , and a carrier or diluent.

15 . The item impregnated with, coated in or covered by a composition comprising the peptide as defined in claim 1 , wherein the item is selected from the group consisting of: a medical device, medical instrument, medical implement, prosthetic, implantable device or material, wound dressing and a biologically compatible material.

Assignees

• Univ Barcelona Autonoma
• Univ Pompeu Fabra

Inventors

• Boix Borrás Ester
• Torrent Burgas Marc
• Andreu David

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• C07K14/001 Primary

  by chemical synthesis · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N9/22 Primary

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title